Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) and Aeterna Zentaris (Nasdaq: AEZS) reported that their colorectal cancer treatment Perifosine failed a Phase 3 clinical trial. Shares of Keryx plummeted $3.30 to $1.68 while Aeterna stock plunged $1.39 to $0.75.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here